Amgen Licenses IL-33 Inhibitor For Asthma, COPD To Genentech
This article was originally published in Scrip
Executive Summary
Amgen Inc. will continue to sharpen its focus on six key therapeutic areas by licensing its Phase I interleukin-33 (IL-33) inhibitor AMG 282 to the Roche company Genentech Inc., which will study the monoclonal antibody in asthma and chronic obstructive pulmonary disease (COPD).